Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Starlight 3: Long-term safety of fezolinetant in Japanese women with vasomotor symptoms of menopause
jRCT2031230584Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in menopause and hot flash comparing Fezolinetant with Placebo (2 arms). Primary endpoint: Frequency and severity of adverse events. Started Feb 2024; status: completed.
02
Drugs
fezolinetant
03
Conditions
menopausehot flash
Beyond the preview
Go deeper on jRCT2031230584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230584.